PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28095420-8 2017 Transfection of cultured neurons with GluN2A-P552R prolonged EPSPs, and triggered pronounced dendritic swelling in addition to excitotoxicity, which were both attenuated by memantine. Memantine 173-182 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 38-44 34776984-6 2021 Intriguingly, we found that while treatment with memantine can effectively block GluN2A-P552R-mediated dendrotoxicity, treatment with ketamine does not, despite the fact that both drugs work as open NMDAR channel blockers. Memantine 49-58 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 81-87 34776984-7 2021 Interestingly, we found that neurons expressing GluN2A-P552R were more vulnerable to an excitotoxic insult-an effect that, in this case, could be equally rescued by both memantine and ketamine. Memantine 170-179 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 48-54 34776984-9 2021 The differences between memantine and ketamine in halting GluN2A-P552R dendrotoxicity could not be explained by NMDA antagonist induced changes in MAP or Src kinase activation, previously shown to participate in NMDA-induced excitotoxicity. Memantine 24-33 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 58-64 34270920-4 2021 Specifically, memantine attenuated alpha-synuclein-induced expression of clathrin and EEA1, and increased expression of NR2A subunits. Memantine 14-23 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 120-124 34270920-6 2021 The present study demonstrated that memantine modulates extracellular alpha-synuclein propagation by inhibiting interactions between alpha-synuclein and NR2A subunits, which leads to neuroprotective effects on nigral dopaminergic neurons against alpha-synuclein-enriched conditions. Memantine 36-45 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 153-157 32765929-0 2020 GRIN2A -Related Severe Epileptic Encephalopathy Treated with Memantine: An Example of Precision Medicine. Memantine 61-70 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 0-6 32765929-4 2020 GRIN2A gene encodes for a subunit of N-methyl-D-aspartate (NMDA) receptor and it has been suggested from in vitro studies and few case reports that memantine, a NMDA receptor antagonist, was shown to reduce seizures in patients with GRIN2A mutations. Memantine 148-157 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 0-6 32765929-4 2020 GRIN2A gene encodes for a subunit of N-methyl-D-aspartate (NMDA) receptor and it has been suggested from in vitro studies and few case reports that memantine, a NMDA receptor antagonist, was shown to reduce seizures in patients with GRIN2A mutations. Memantine 148-157 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 233-239 32765929-5 2020 Here, we describe a patient with a novel GRIN2A mutation and severe drug-resistant ES who became seizure free with memantine. Memantine 115-124 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 41-47 30870728-6 2019 There are also cases where functional disturbances caused by the gene defect may not be corrected by existing AEDs, but can be countered by medications already available in the market for other indications (e.g., memantine has been used to treat the epileptic encephalopathy caused by a specific gain-of-function GRIN2A mutation), thus making "drug repurposing" a valuable tool for personalized epilepsy therapies. Memantine 213-222 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 313-319 20955720-0 2011 Quantification of the Mg2+-induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1/GluN2A NMDARs. Memantine 67-76 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 128-134 24839611-0 2014 GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Memantine 84-93 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 0-6 24839611-5 2014 In vitro analysis with NMDA receptor blockers indicated that GLuN2A-L812M-containing NMDARs retained their sensitivity to the use-dependent channel blocker memantine; while screening of a previously reported GRIN2A mutation (N615K) with these compounds produced contrasting results. Memantine 156-165 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 61-67 24839611-5 2014 In vitro analysis with NMDA receptor blockers indicated that GLuN2A-L812M-containing NMDARs retained their sensitivity to the use-dependent channel blocker memantine; while screening of a previously reported GRIN2A mutation (N615K) with these compounds produced contrasting results. Memantine 156-165 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 208-214 20955720-3 2011 This study quantifies the extent to which Mg(2+) alters the potency of the block produced by both amantadine and memantine at human recombinant GluN1/GluN2A NMDARs. Memantine 113-122 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 150-156 20955720-5 2011 Amantadine and memantine blocked human GluN1/GluN2A NMDARs in a voltage-dependent manner with IC(50) values (at -80 mV) of 49 +- 6 muM (n = 7) and 1.0 +- 0.3 muM (n = 7), respectively. Memantine 15-24 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 45-51 20955720-7 2011 Similarly in the presence of amantadine or memantine the potency of Mg(2+) in blocking GluN1/GluN2A NMDARs was reduced. Memantine 43-52 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 93-99 19371579-4 2009 In the present study we compared the potency of memantine, ketamine and (+)MK-801 in binding to NMDA receptors in post-mortem human cortical tissue and to antagonize intracellular Ca(2+) responses of human GluN1/GluN2A receptors expressed in HEK-293 cells. Memantine 48-57 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 212-218 19371579-6 2009 Memantine was confirmed to be a moderate affinity (IC(50) at -70 mV of 0.79+/-0.02 microM, Hill=0.92+/-0.02), strongly voltage-dependent (delta=0.90+/-0.09) uncompetitive antagonist of human GluN1/GluN2A receptors. Memantine 0-9 glutamate ionotropic receptor NMDA type subunit 2A Homo sapiens 197-203